CinCor Pharma to Participate in Jefferies Biotech on the Bay Summit

Rhea-AI Summary

CinCor Pharma announced its participation in the Jefferies Biotech on the Bay Summit on April 26-27, 2022, in Miami, Florida. The management will hold one-on-one investor meetings, and interested investors should reach out to their Jefferies representatives.

Founded in 2018, CinCor is a clinical-stage biopharmaceutical company focused on treating cardio-renal diseases. Its lead product, CIN-107, is an oral small molecule inhibitor targeting aldosterone synthase, aimed at combating hypertension and primary aldosteronism in patients with significant unmet needs.

WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) --  CinCor Pharma, Inc. (“CinCor”) today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida.

The CinCor management team will participate in one-on-one investor meetings during the event. Investors interested in meeting with CinCor at the conference should contact their Jefferies representative.

About CinCor
CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, is in clinical development for the treatment of hypertension and primary aldosteronism.

About CIN-107
CIN-107 is a highly selective, oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland, in development for patient populations with significant unmet medical needs, including treatment-resistant hypertension and primary aldosteronism. Hypertension, which is defined by the American College of Cardiology and the American Heart Association as resting blood pressure above 130/80 mm Hg, is generally acknowledged to be one of the most common preventable risk factors for premature death worldwide. Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke, and kidney disease, amongst other diseases. It is estimated that as much as 20% of the global population suffers from hypertension, including nearly one-half of the adult population in the U.S., or 116 million hypertensive patients.   

Contacts:	Investors:
Terry Coelho	Bob Yedid
CinCor Pharma, Inc.	LifeSci Advisors
EVP, CFO and CBDO	ir@CinCor.com

FAQ

What event is CinCor Pharma participating in on April 26-27, 2022?

CinCor Pharma is participating in the Jefferies Biotech on the Bay Summit.

Where will the Jefferies Biotech on the Bay Summit take place?

The summit will be held in Miami, Florida.

What will CinCor's management team do at the summit?

They will participate in one-on-one investor meetings.

What is CIN-107 and what is its purpose?

CIN-107 is a selective oral small molecule inhibitor of aldosterone synthase, designed to treat hypertension and primary aldosteronism.

Why is hypertension a significant health issue?

Hypertension is a major preventable risk factor for premature death, affecting around 20% of the global population and nearly half of U.S. adults.